Rostina Yoon

Vice President, Strategy & Delivery
Syneos Health

Rostina Yoon is a seasoned pharmacist with over 34 years of extensive experience in drug development. She has worked with both Clinical Research Organizations (CROs) and pharmaceutical companies, holding roles that span across clinical research monitoring, project management, and strategic leadership.
 
Throughout her career, Rostina has successfully conducted phase I to IV trials across various therapeutic indications, including significant phase II and phase III studies. Her contributions have been instrumental in the approval of several key drugs currently on the market.
Rostina has been involved in several high-profile projects that have set new benchmarks in clinical research. She is particularly known for her innovative approaches to clinical trial design and execution. Her passion lies in leveraging advanced technologies, particularly artificial intelligence (AI), to transform the way clinical trials are conducted, ensuring higher efficiency and accuracy.
 
One of Rostina's notable achievements is her pioneering use of AI to optimize study design and develop effective strategies. By integrating AI into the clinical trial process, she has significantly improved the efficiency of trials. Her practical application of AI in clinical research showcases her adaptability and forward-thinking approach.
 
As a senior leader, Rostina is known for her exceptional therapeutic and clinical development knowledge. She brings an innovative approach to creating solutions that transform patients' lives. Her ability to foster interdisciplinary collaboration and her problem-solving mindset have earned her recognition as a value creator and innovator in the field.
 
Looking ahead, Rostina envisions a future where AI and other advanced technologies play a central role in clinical research, driving innovations that improve patient outcomes and streamline drug development processes. Her commitment to excellence and her visionary approach make her a respected leader and a valuable asset to the field of clinical research.


​

Speech title & Synopsis

Beyond Guesswork: Using AI to Forecast and Optimize Clinical Trials

Introduction
Protocol design is one of the most critical and error-prone phases of clinical development. Trials often revolve around idealized patient profiles, leading to costly amendments and recruitment delays. The complexity and unstructured nature of protocol data frequently result in the under-utilization of valuable insights from past clinical trials.
 
The Challenge
A common challenge in protocol design is the focus on an ideal target patient profile based on the scientific understanding of the mechanism of action and the disease. However, this ideal patient population may not be realistic, often necessitating protocol amendments during the study to find patients who fit the criteria. Additionally, the desire to collect extensive data to satisfy scientific curiosity can lead to increased site and patient burden, further complicating recruitment and retention.
 
The Solution
Our GenAI-powered platform addresses these challenges.  It enables intelligent protocol design and forecasts recruitment potential. Leveraging the insights from over 470,000 historical protocols, it performs advanced similarity searches, comparative analyses, and patient burden assessments. This robust capability allows for evidence-based adjustments, optimizing study designs and significantly enhancing feasibility.
 
Benefits
Attendees will gain insights into how GenAI-based design tools can accelerate study start-up, reduce protocol amendments, and create more inclusive, site-friendly trials. By utilizing AI to forecast and optimize clinical trials, we move beyond guesswork into a realm of strategic planning.
 
Conclusion
Join us as we explore the transformative power of AI in clinical trial protocol analysis and insights, delivering smarter, faster, and more inclusive trials, and transforming protocol development from an art into a data-driven science.